Quinidine Trial in a Patient with Epilepsy of Infancy with Migrating Focal Seizure and KCNT1 Mutation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Epilepsy of infancy with migrating focal seizure (MFEI) is an early-onset epileptic encephalopathy characterized by randomly migrating focal seizures and psychomotor deterioration. It is associated with mutations in a variety of genes, with potassium sodium-activated channel subfamily T member 1 (KCNT1) being an example. Previously reported KCNT1 mutations in MFEI are gain-of-function mutations. Therefore, quinidine therapy targeted at reduction of pathologically increased KCNT1 channel-mediated potassium conductance has been proposed as a target treatment for MEFI with KCNT1 mutation. The authors report a case involving a patient with MFEI and a missense mutation in KCNT1 (c.7129G>A; p.Phe346Leu) treated with quinidine therapy. Seizure activity was poorly responsive to quinidine.
Abstract
Epilepsy of infancy with migrating focal seizure (MFEI) is an early-onset epileptic encephalopathy characterized by randomly migrating focal seizures and psychomotor deterioration. It is associated with mutations in a variety of genes, with potassium sodium-activated channel subfamily T member 1 (KCNT1) being an example. Previously reported KCNT1 mutations in MFEI are gain-of-function mutations. Therefore, quinidine therapy targeted at reduction of pathologically increased KCNT1 channel-mediated potassium conductance has been proposed as a target treatment for MEFI with KCNT1 mutation. The authors report a case involving a patient with MFEI and a missense mutation in KCNT1 (c.7129G>A; p.Phe346Leu) treated with quinidine therapy. Seizure activity was poorly responsive to quinidine.
참고문헌 (20)
- Coppola G, "Migrating partial seizures in infancy : a malignant disorder with developmental arrest", Epilepsia, 36, pp.1017~1024 (1995)
- Coppola G, "Malignant migrating partial seizures in infancy : an epilepsy syndrome of unknown etiology", Epilepsia, 50(Suppl 5), pp.49~51 (2009)
- Marsh E, "Migrating partial seizures in infancy : expanding the phenotype of a rare seizure syndrome", Epilepsia, 46, pp.568~572 (2005)
- McTague A, "Migrating partial seizures of infancy: expansion of the electroclinical, radiological and pathological disease spectrum", Brain, 136, pp.1578~1591 (2013)
- Barcia G, "De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy", Nat Genet, 44, pp.1255~1259 (2012)
- Poduri A, "Homozygous PLCB1 deletion associated with malignant migrating partial seizures in infancy", Epilepsia, 53, pp.E146~e150 (2012)
- Freilich ER, "Novel SCN1A mutation in a proband with malignant migrating partial seizures of infancy", Arch Neurol, 68, pp.665~671 (2011)
- Milh M, "Novel compound heterozygous mutations in TBC1D24cause familial malignant migrating partial seizures of infancy", Hum Mutat, 34, pp.869~872 (2013)
- De Filippo MR, "Lack of pathogenic mutations in six patients with MMPSI", Epilepsy Res, 108, pp.340~344 (2014)
- Ishii A, "A recurrent KCNT1 mutation in two sporadic cases with malignant migrating partial seizures in infancy", Gene, 531, pp.467~471 (2013)
- Yuan A, "The sodium-activated potassium channel is encoded by a member of the Slo gene family", Neuron, 37, pp.765~773 (2003)
- Milligan CJ, "KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine", Ann Neurol, 75, pp.581~590 (2014)
- Mikati MA, "Quinidine in the treatment of KCNT1-positive epilepsies", Ann Neurol 2015;, 78, pp.995~999 (2015)
- Ochs HR, "Entry of quinidine into cerebrospinal fluid", Am Heart J, 100, pp.341~346 (1980)
- Data JL, "Interaction of quinidine with anticonvulsant drugs", N Engl J Med, 294, pp.699~702 (1976)
- Ben-Ari Y, "Effects of seizures on developmental processes in the immature brain", Lancet Neurol, 5, pp.1055~1063 (2006)
- Kilpinen H, "Common genetic variation drives molecular heterogeneity in human iPSCs", Nature, 546, pp.370~375 (2017)
- Lee G, "Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs", Nature, 461, pp.402~406 (2009)
- Hsu PD, "Development and applications of CRISPR-Cas9 for genome engineering", Cell, 157, pp.1262~1278 (2014)
- Suzuki K, "In vivo genome editing via CRISPR", Cas9 mediated homology-independent targeted integration, 2016, pp.540, 144~149